Astria Therapeutics, Inc. (ATXS)
NASDAQ
Market Cap
$560.39M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
15 of 963
Rank in Industry
12 of 552
Largest Insider Buys in Sector
ATXS Stock Price History Chart
ATXS Stock Performance
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Insider Activity of Astria Therapeutics, Inc.
Over the last 12 months, insiders at Astria Therapeutics, Inc. have bought $34.59M and sold $247,303 worth of Astria Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Astria Therapeutics, Inc. have bought $17.2M and sold $247,303 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (director) — $622.58M.
The last purchase of 2,481,350 shares for transaction amount of $30M was made by PERCEPTIVE ADVISORS LLC (director) on 2024‑02‑01.
List of Insider Buy and Sell Transactions, Astria Therapeutics, Inc.
| 2024-04-01 | Sale | Chief Medical Officer | 10,000 0.0183% | $13.59 | $135,939 | -21.87% | ||
| 2024-02-01 | director | 2.48M 5.6893% | $12.09 | $30M | -17.26% | |||
| 2024-01-29 | Sale | Chief Medical Officer | 9,200 0.0208% | $11.15 | $102,552 | -5.70% | ||
| 2024-01-26 | Sale | Chief Medical Officer | 800 0.0022% | $11.02 | $8,812 | +4.06% | ||
| 2023-12-21 | director | 740,000 2.0257% | $6.20 | $4.59M | +77.92% | |||
| 2023-10-16 | director | 1.07M 3.9128% | $6.51 | $7M | +53.54% | |||
| 2022-12-19 | director | 908,265 6.1619% | $11.01 | $10M | -10.50% | |||
| 2021-11-19 | Chief Commercial Officer | 100 0.0008% | $6.70 | $670 | -6.97% | |||
| 2015-06-30 | 10 percent owner | 391,090 2.5125% | $12.00 | $4.69M | -41.69% | |||
| 2015-06-30 | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | ||||
| 2015-06-30 | 10 percent owner | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | |||
| 2015-06-30 | 10 percent owner | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | |||
| 2015-06-30 | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | ||||
| 2015-06-30 | director | 258,776 1.6625% | $12.00 | $3.11M | -41.69% |
Insider Historical Profitability
<0.0001%
| PERCEPTIVE ADVISORS LLC | director | 4873721 8.6361% | $9.93 | 4 | 0 | <0.0001% |
| Morabito Christopher | Chief Medical Officer | 0 0% | $9.93 | 0 | 3 | |
| SVLSF V, LLC | 10 percent owner | 2798528 4.9589% | $9.93 | 1 | 0 | |
| GALAKATOS NICHOLAS | 2752488 4.8773% | $9.93 | 1 | 0 | ||
| Clarus Lifesciences II, L.P. | 10 percent owner | 2752488 4.8773% | $9.93 | 1 | 0 | |
| MedImmune Ventures, Inc. | 10 percent owner | 1632652 2.893% | $9.93 | 1 | 0 | |
| Laufer Ron | 1632652 2.893% | $9.93 | 1 | 0 | ||
| George Jean | director | 1133943 2.0093% | $9.93 | 1 | 0 | |
| Komjathy Andrew | Chief Commercial Officer | 100 0.0002% | $9.93 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Perceptive Advisors | $91.25M | 11.81 | 6.49M | +61.97% | +$34.91M | 0.06 | |
| Tcg Crossover Management Llc | $74.3M | 9.61 | 5.28M | New | +$74.3M | 0.12 | |
| RA Capital Management, L.P. | $62.12M | 8.04 | 4.41M | New | +$62.12M | 0.06 | |
| Fidelity Investments | $60.79M | 7.87 | 4.32M | -10.07% | -$6.81M | <0.01 | |
| Vr Adviser Llc | $50.79M | 6.57 | 3.61M | +11.87% | +$5.39M | 2.47 | |
| BlackRock | $50.47M | 6.53 | 3.59M | +64.13% | +$19.72M | <0.01 | |
| Fairmount Funds Management LLC | $50.02M | 6.47 | 3.55M | 0% | +$0 | 5.45 | |
| The Vanguard Group | $35.69M | 4.62 | 2.54M | +23.36% | +$6.76M | <0.01 | |
| Vivo Capital | $32.78M | 4.24 | 2.33M | -6.19% | -$2.16M | 2.86 | |
| State Street | $31.24M | 4.04 | 2.22M | +319% | +$23.79M | <0.01 | |
| Driehaus Capital Management LLC | $24.84M | 3.21 | 1.76M | +314.93% | +$18.86M | 0.25 | |
| Millennium Management LLC | $23.47M | 3.04 | 1.67M | +657.6% | +$20.38M | 0.02 | |
| Adage Capital Partners Gp L L C | $22.54M | 2.92 | 1.6M | New | +$22.54M | 0.04 | |
| Cormorant Asset Management Lp | $18.3M | 2.37 | 1.3M | New | +$18.3M | 0.85 | |
| Logos Global Management Lp | $17.52M | 2.27 | 1.24M | +128.45% | +$9.85M | 1.89 | |
| Geode Capital Management | $14.1M | 1.82 | 1M | +43.68% | +$4.29M | <0.01 | |
| Avidity Partners Management Lp | $13.82M | 1.79 | 982,000 | New | +$13.82M | 0.53 | |
| Artal Group S A | $12.45M | 1.61 | 884,214 | New | +$12.45M | 0.05 | |
| Citadel Advisors LLC | $12.36M | 1.6 | 878,151 | +511.28% | +$10.34M | 0.01 | |
| Affinity Asset Advisors | $11.9M | 1.54 | 845,606 | -42.34% | -$8.74M | 0.18 | |
| Northern Trust | $6.05M | 0.78 | 429,893 | +41.83% | +$1.78M | <0.01 | |
| Sio Capital Management LLC | $5.77M | 0.75 | 410,267 | New | +$5.77M | 2.08 | |
| Tri Locum Partners Lp | $5.2M | 0.67 | 369,549 | -31.94% | -$2.44M | 0.43 | |
| PFM Health Sciences | $4.6M | 0.6 | 327,045 | New | +$4.6M | 0.13 | |
| Caption Management Llc | $4.22M | 0.55 | 300,000 | New | +$4.22M | 0.13 | |
| Invesco | $4.16M | 0.54 | 295,450 | +2,471.81% | +$4M | <0.01 | |
| Morgan Stanley | $3.17M | 0.41 | 225,555 | -40.26% | -$2.14M | <0.0001 | |
| DAFNA Capital Management, LLC | $3.14M | 0.41 | 223,265 | -50.28% | -$3.18M | 0.08 | |
| Goldman Sachs | $3.01M | 0.39 | 213,534 | +1,203.94% | +$2.77M | <0.01 | |
| Nuveen | $2.92M | 0.38 | 207,197 | +102.8% | +$1.48M | <0.01 | |
| Citigroup | $2.23M | 0.29 | 158,575 | +3,245.46% | +$2.17M | <0.01 | |
| Rafferty Asset Management Llc | $2.2M | 0.29 | 156,529 | New | +$2.2M | 0.01 | |
| Altium Capital Management Lp | $2.01M | 0.26 | 142,532 | -80.47% | -$8.27M | 0.24 | |
| Ikarian Capital LLC | $1.98M | 0.26 | 140,687 | -62.46% | -$3.3M | 0.27 | |
| Barclays | $1.9M | 0.25 | 135,207 | +173.62% | +$1.21M | <0.01 | |
| Charles Schwab | $1.84M | 0.24 | 131,069 | +51.03% | +$623,339.47 | <0.0001 | |
| BNY Mellon | $1.83M | 0.24 | 130,106 | +41.03% | +$532,780.99 | <0.0001 | |
| UBS | $1.77M | 0.23 | 126,048 | +248.47% | +$1.27M | <0.01 | |
| Toroso Investments Llc | $1.66M | 0.22 | 118,200 | New | +$1.66M | 0.01 | |
| Wellington Management Company | $1.63M | 0.21 | 116,057 | New | +$1.63M | <0.0001 | |
| GHOST TREE CAPITAL LLC | $1.62M | 0.21 | 115,000 | -65.67% | -$3.1M | 0.02 | |
| Sphera Fund | $1.59M | 0.21 | 112,842 | -90.2% | -$14.61M | 0.01 | |
| Bank of America | $1.54M | 0.2 | 109,400 | +99.04% | +$766,186.20 | <0.0001 | |
| Ubs Oconnor Llc | $1.52M | 0.2 | 108,120 | +38.4% | +$422,250.00 | 0.07 | |
| Simplex Trading Llc | $1.36M | 0.18 | 96,681 | +516.59% | +$1.14M | 0.04 | |
| Marshall Wace | $988,994.00 | 0.13 | 70,241 | +391.2% | +$787,649.85 | <0.01 | |
| RhumbLine Advisers | $884,168.00 | 0.11 | 62,819 | +67.03% | +$354,812.89 | <0.01 | |
| AllianceBernstein | $694,883.00 | 0.09 | 49,370 | New | +$694,883.00 | <0.0001 | |
| Polar Asset Management Partners Inc | $679,823.00 | 0.09 | 48,300 | New | +$679,823.00 | 0.01 | |
| Renaissance Technologies | $583,000.00 | 0.08 | 41,400 | +191.55% | +$383,033.82 | <0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.